Skip to main content
. 2022 Aug 24;26(1):69–79. doi: 10.1007/s10123-022-00273-6

Table 2.

Prevalence of SC + according to the presence of clinical/ultrasound signs of genital tract inflammation (GTI) in the subgroups studied

n SC +  Gram +  Gram −  Gram + / − 
Group A n. 452

n. 113/452

(25.0%) a

n. 46/113

(40.7%)

n. 35/113 (31.0%) n. 32/113 (28.3%)
  Subgroup A1

n. 367/452

(81.2%) b

n. 99/367

(26.9%)

n. 41/99

(41.4%)

n. 30/99

(30.3%)

n. 28/99

(28.3%)

  Subgroup A2

n. 85/452

(18.8%) c

n. 14/85

(16.4%)

n. 5/14

(35.7%)

n. 5/14

(35.7%)

n. 4/14

(28.6%)

Group B n. 478

n. 87/478

(18.2%)

n. 37/87

(42.5%)

n. 29/87

(33.4%)

n. 21/87

(24.1%)

  Subgroup B1 285/478 (59.6%)

n. 75/285

(26.3%)

n. 32/75

(42.7%)

n. 25/75

(33.3%)

n. 18/75

(24.0)

  Subgroup B2 193/478 (40.4%)

n. 12/193

(6.2%)

n. 5/12

(41.7%)

n. 4/12

(33.3%)

n. 3/12

(25.0%)

Control n. 30

n. 1/30

(3.3%)

n. 1/1

(100.0%)

  Control 1 1/30 (3.3%)

n. 1/1

(100.0%)

n. 1/1

(100.0%)

  Control 2 29/30 (96.7%)

n. 0/29

(–)

Subgroups A1, B1 and control 1 subjects affected by GTI, subgroup A2, B2 and control 2 subjects without GTI

ap = 0.012 vs. group B

bp = 0.001 vs. group B1

cp = 0.001 vs. group B2